Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- Myasthenia Gravis
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Symptoms and disease pathophysiology of myasthenia gravis (MG) vary considerably with each patient, and their individual preferences and priorities add to the need for individualized treatment of this autoimmune disease. Research in MG has grown substantially in recent years. New treatments have the potential of being both effective and well tolerated, addressing the trade-off of choosing either efficacy or tolerability when selecting treatments. Promising investigational treatments that may become available in the future may allow more patients than ever before to achieve an asymptomatic state, with the ultimate goal being to turn off abnormal antibody production.
- Bipolar Disorder
- Bipolar Depression
- Depression
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Bipolar disorder presents on a spectrum, with bipolar depression on one end and bipolar I on the other and a host of other presentations in between. As guidelines are updated and new treatments become available, developing individualized treatment regimens is key and collaboration between clinician and patient and family is critical in optimizing patient outcomes. Clinicians should use measurement-based care to assess whether treatment changes are necessary, which requires engaging with the patient to monitor efficacy and manage side effects.
- Schizophrenia/ Schizoaffective Disorders
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Schizophrenia affects 1% of the world’s population largely during a patient’s most productive years. Multiple treatments are available, however many gaps to recovery exist. Learn from experts diagnostic criteria for and defining recovery in schizophrenia.
- Schizophrenia/ Schizoaffective Disorders
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Negative symptoms contribute to poor functional outcomes in schizophrenia. Evaluating different symptom domains and understanding the disorder’s reward circuitry can help with intervention and patients’ leading more fulfilling lives.
- Schizophrenia/ Schizoaffective Disorders
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Side effects from medication have the greatest impact on adherence for patients with Schizophrenia. They lower quality of life, daily functioning, and satisfaction.
- Schizophrenia/ Schizoaffective Disorders
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Balancing symptoms and side effects is difficult when treating patients with schizophrenia. New approaches to treatment and new therapies in the pipeline offer hope for this difficult-to-treat mental health disorder.
- Wilson Disease
- Genetics
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Due to Wilson disease myriad manifestations, its rarity, and its range of symptoms, differential diagnosis may be challenging, leading to delays in treatment. This Neuroscience Commentary reviews diagnostic acumen and the latest updates in the field.
- Alzheimer Disease
- Cognition
- Dementia
- Geriatric Psychiatry
- Neurology
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Among the most transformative Alzheimer Disease discoveries is the existence of biomarkers which can manifest decades before onset of disease-related dementia.
- Alzheimer Disease
- Cognition
- Dementia
- Geriatric Psychiatry
- Neurology
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$0.00
Navigating the associated differential diagnosis in AD is essential as various causes of cognitive impairment require different treatment strategies.
- Cardiology
- Comorbidity
- Education
- Integrated Care
- Medical Conditions
- Pulmonary Disease
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
Pulmonary arterial hypertension requires risk stratification to develop goal-directed treatment plans, including combination therapy targeting multiple pathways.